Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy
- 9 May 2007
- journal article
- review article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 12 (2) , 97-104
Abstract
Acute heart failure syndromes (AHFS) represent the most common discharge diagnosis in patients over age 65 years, with an exceptionally high mortality and readmission rates at 60–90 days. Recent surveys and registries have generated important information concerning the clinical characteristics of patients with AHFS and their prognosis. Most patients with AHFS present either with normal systolic blood pressure or elevated blood pressure. Patients who present with elevated systolic blood pressure usually have pulmonary congestion, a relatively preserved left ventricular ejection fraction (LVEF), are often elderly women, and their symptoms develop typically and abruptly. Patients with normal systolic blood pressure present with systemic congestion, reduced LVEF, are usually younger with a history of chronic HF, and have symptoms that develop gradually over days or weeks. In addition to the abnormal hemodynamics (increase in pulmonary capillary wedge pressure and/or decrease in cardiac output) that characterize patients with AHFS, myocardial injury, which may be related to a decrease in coronary perfusion and/or further activation of neurohormones and renal dysfunction, probably contributes to short-term and post-discharge cardiac events. Patients with AHFS also have significant cardiac and noncardiac underlying conditions that contribute to the pathogenesis of AHFS, including coronary artery disease (ischemia, hibernating myocardium, and endothelial dysfunction), hypertension, atrial fibrillation, and type 2 diabetes mellitus. Therefore, the targets of therapy for AHFS should be not only to improve symptoms and hemodynamics but also to preserve or improve renal function, prevent myocardial damage, modulate neurohumoral and inflammatory activation, and to manage other comorbidities that may cause and/or contribute to the progression of this syndrome.Keywords
This publication has 48 references indexed in Scilit:
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trialAcute Cardiac Care, 2007
- Heart Disease and Stroke Statistics—2006 UpdateCirculation, 2006
- Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failureInternational Journal of Cardiology, 2005
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005
- Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT)JACC, 2004
- Vasopressin: a new target for the treatment of heart failureAmerican Heart Journal, 2003
- Outcomes in heart failure patients with preserved ejection fractionJACC, 2003
- Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failureThe American Journal of Cardiology, 1982
- Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6Cytogenetic and Genome Research, 1976
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976